In the SUMMIT imaging substudy, participants who received tirzepatide had a greater decrease in left ventricular mass and fat around the heart than those who received placebo. Participants had obesity and heart failure with preserved ejection fraction (HFpEF). The scans measured how heart structure changed over 52 weeks [1].
What the scans showed
The substudy used cardiac MRI to measure the muscle mass of the left ventricle, the heart’s main pumping chamber, and paracardiac fat, which includes fat in and around the sac that encloses the heart. Of the 175 people scanned at baseline, 106 had usable scans at baseline and week 52: 50 on tirzepatide and 56 on placebo [1].
Compared with placebo, the change with tirzepatide was −11 g for left ventricular mass (95% confidence interval −19 to −4 g) and −45 mL for paracardiac fat (95% confidence interval −69 to −22 mL). The estimates come from participants with two usable scans, about three in five of those scanned at baseline [1].
How the scans relate to heart failure events
Our guide to tirzepatide’s heart evidence covers several trials with different patient groups and outcomes. The main SUMMIT trial specifically enrolled 731 adults with obesity and heart failure with an ejection fraction of at least 50%. Over a median 104 weeks, 9.9% on tirzepatide and 15.3% on placebo experienced cardiovascular death or a worsening heart-failure event (hazard ratio 0.62, 95% confidence interval 0.41–0.95) [2].
Worsening heart failure occurred in 8.0% on tirzepatide and 14.2% on placebo. Cardiovascular death alone was less common and the estimate was imprecise: 2.2% versus 1.4% (hazard ratio 1.58, 95% confidence interval 0.52–4.83) [2]. The imaging authors suggested the smaller heart muscle mass and lower fat volume could have contributed to the clinical result. The substudy did not establish that either imaging change caused the difference in heart failure events [1].